Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds


VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE


A case for improved carrier screening

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data


Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis


CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics


The search for molecular glue in targeted disease control


Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says


Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p
Glycosaminoglycans as Multifunctional Anti-Elastase and Anti-Inflammatory Drugs in Cystic Fibrosis L